Gilead Sciences (GILD) trades near the lows though the biotech is buying stock back hand over fist. In total, the company recently completed a $15 billion stock buyback started only a year ago. The incredible part is that management was willing to pay an average price of $100 for the $10 billion spent in the open market. With the market price down to $113 billion, the amount spent on stock buybacks is an incredible 13% of the current valuation. With the stock trading under 7x EPS estimates, do you really want to pass up this opportunity? Disclosure: No position